GKL-006Allo Injection in Patients With Advanced Solid Tumors
A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GKL-006Allo Injection in Patients With Solid Tumors
研究概览
详细说明
This Phase 1 study will evaluate GKL-006Allo Injection in participants with advanced or metastatic solid tumors who have failed or are intolerant to standard therapy.
The study includes single-dose and multiple-dose treatment, with a potential dose-expansion stage to further evaluate selected dose level according to protocol-specified criteria. The single-dose and multiple-dose stages are designed to characterize safety, tolerability, and biological activity across protocol-specified dose levels.
Participants will receive GKL-006Allo Injection according to the study protocol and will undergo scheduled safety monitoring, tumor assessments, pharmacokinetic and pharmacodynamic sampling, and immunogenicity testing during treatment and follow-up.
研究类型
注册 (估计的)
阶段
- 阶段1
联系人和位置
学习联系方式
- 姓名:Cancer Hospital Chinese Academy of Medical Sciences
- 电话号码:+86-316-5916013
- 邮箱:lining@cisams.ac.cn
学习地点
-
-
Beijing Municipality
-
Beijing、Beijing Municipality、中国、100021
- Cancer Hospital Chinese Academy of Medical Sciences
-
接触:
- GCP Center
- 电话号码:0316-5916013
- 邮箱:lining@cisams.ac.cn
-
-
参与标准
资格标准
适合学习的年龄
- 成人
- 年长者
接受健康志愿者
描述
Inclusion Criteria:
- Able to understand and voluntarily sign the informed consent form.
- Aged 18 to 75 years.
- Histologically, cytologically or clinical confirmed unresectable locally advanced or metastatic solid tumor that has failed standard therapy.
- At least one measurable tumor lesion during screening according to RECIST v1.1.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 and life expectancy of at least 3 months.
- Adequate hematologic and organ function.
- Participants of childbearing potential must agree to use at least one medically accepted contraceptive method during study treatment and for 6 months after the end of study treatment.
- Able to communicate with the investigator, comply with study visits, and understand and follow study requirements.
Exclusion Criteria:
- Recently received radical radiotherapy or other anti-tumor therapy.
- Known hypersensitivity to any component of the study treatment.
- Prior history or concurrent malignancy that has not been cured.
- Active infection, known or suspected autoimmune disease.
- Last anti-tumor treatment toxicity not yet recovered to suitable status.
- Other organ dysfunction or situations deemed inappropriate by the investigator.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:不适用
- 介入模型:顺序分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:GKL-006Allo Injection
Natural killer T cells (NKT) are a type of special lymphocyte discovered in recent years that mediate both innate and adaptive immunity, and are considered the fourth type of lymphocyte.
GKL-006Allo is an allogeneic iNKT cell.
|
GKL-006Allo Injection is an allogeneic invariant natural killer T (iNKT) cell therapy.
It will be administered according to the dose level, dosing schedule, and treatment stage specified in the protocol.
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Number of Participants With Dose-Limiting Toxicities (DLTs)
大体时间:From the first dose through the end of the DLT observation period, assessed up to 28 days.
|
Dose-limiting toxicities will be assessed according to protocol-defined DLT criteria.
|
From the first dose through the end of the DLT observation period, assessed up to 28 days.
|
|
Incidence and Severity of Adverse Events
大体时间:From the first dose of study treatment until 28 days after the pointed dose of study treatment. The safety monitor will be continued until the end of the study, up to 18 months.
|
Safety will be assessed by the incidence and severity of adverse events, serious adverse events, laboratory abnormalities, electrocardiogram abnormalities, physical examination findings, and vital sign abnormalities.
|
From the first dose of study treatment until 28 days after the pointed dose of study treatment. The safety monitor will be continued until the end of the study, up to 18 months.
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Progression-Free Survival (PFS)
大体时间:From the first dose of study treatment until disease progression or death from any cause, whichever occurs first, assessed up to 18 months.
|
Progression-free survival is defined as the time from the first dose of study treatment to the first documented disease progression or death from any cause, whichever occurs first, according to RECIST v1.1.
|
From the first dose of study treatment until disease progression or death from any cause, whichever occurs first, assessed up to 18 months.
|
|
Overall Survival (OS)
大体时间:From the first dose of study treatment until death from any cause, assessed up to 18 months.
|
Overall survival is defined as the time from the first dose of study treatment to death from any cause.
|
From the first dose of study treatment until death from any cause, assessed up to 18 months.
|
|
Change From Baseline in EORTC QLQ-C30 Scale Scores
大体时间:Baseline and scheduled post-baseline assessments, up to 18 months.
|
Health-related quality of life will be assessed using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30).
Scores for each scale range from 0 to 100.
Higher scores on the functional scales and global health status/quality-of-life scale indicate better functioning or quality of life.
|
Baseline and scheduled post-baseline assessments, up to 18 months.
|
|
Immunogenicity
大体时间:From baseline through protocol-specified immunogenicity sampling time points, assessed up to 180 days.
|
GKL-006 Alloantibodies (ADA) and their titers, anti-GKL-006 Allo neutralizing antibodies (Nab) and their titers, anti-HLA antibodies, etc. will be tested.
|
From baseline through protocol-specified immunogenicity sampling time points, assessed up to 180 days.
|
|
Disease Control Rate (DCR)
大体时间:From the first dose of study treatment through scheduled tumor assessments, assessed up to 18 months.
|
Disease control rate is defined as the proportion of participants with a best overall response of complete response, partial response, or stable disease according to RECIST v1.1.
|
From the first dose of study treatment through scheduled tumor assessments, assessed up to 18 months.
|
|
Objective Response Rate (ORR)
大体时间:From the first dose of study treatment through scheduled tumor assessments, assessed up to 18 months.
|
Objective response rate is defined as the proportion of participants with a best overall response of complete response or partial response according to RECIST v1.1.
|
From the first dose of study treatment through scheduled tumor assessments, assessed up to 18 months.
|
|
Pharmacokinetic characterization of maximum observed plasma concentration (Cmax)
大体时间:From 60 minutes before the first dose through 150 days.
|
Maximum observed plasma concentration of GKL-006 following intravenous administration according to protocol.
|
From 60 minutes before the first dose through 150 days.
|
|
Pharmacokinetic characterization of time to maximum observed plasma concentration (Tmax)
大体时间:From 60 minutes before the first dose through 150 days.
|
Time to reach the maximum observed plasma concentration of GKL-006 following intravenous administration.
|
From 60 minutes before the first dose through 150 days.
|
|
Pharmacokinetic characterization of area under the plasma concentration-time curve (AUC)
大体时间:From 60 minutes before the first dose through 150 days.
|
Area under the plasma concentration-time curve of GKL-006 following intravenous administration.
|
From 60 minutes before the first dose through 150 days.
|
|
Pharmacokinetic characterization of terminal elimination half-life (t½)
大体时间:From 60 minutes before the first dose through 150 days.
|
Terminal elimination half-life of GKL-006 calculated from plasma concentration-time data following intravenous administration.
|
From 60 minutes before the first dose through 150 days.
|
|
Pharmacodynamic Biomarkers of NK cells
大体时间:From 60 minutes before the first dose through 150 days.
|
Immune cell subsets
|
From 60 minutes before the first dose through 150 days.
|
|
Pharmacodynamic Biomarkers of Peripheral blood TNF-α
大体时间:From 60 minutes before the first dose through 150 days.
|
Immune-related cytokines
|
From 60 minutes before the first dose through 150 days.
|
|
Pharmacodynamic Biomarkers of Peripheral blood IFN-γ
大体时间:From 60 minutes before the first dose through 150 days.
|
Immune-related cytokines
|
From 60 minutes before the first dose through 150 days.
|
合作者和调查者
调查人员
- 首席研究员:Ning Li, MD、Cancer Institute and Hospital, Chinese Academy of Medical Sciences
研究记录日期
研究主要日期
学习开始 (估计的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他研究编号
- GKL006ALLOST01
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.